iFSP1

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

iFSP1  纯度: 99.84%

iFSP1 是 FSP1 (AIFM2) 的选择性有效抑制剂，EC50 值为 103 nM。iFSP1 可选择性地诱导过表达 FSP1 的 GPX4 敲除细胞发生铁死亡 (ferroptosis)。iFSP1 可增强多种人癌细胞系对铁死亡诱导剂的敏感度，如: (1S,3R)-RSL3 (HY-100218A)。

iFSP1

iFSP1 Chemical Structure

CAS No. : 150651-39-1

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥530 In-stock
10 mg ￥480 In-stock
50 mg ￥2130 In-stock
100 mg ￥4000 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

iFSP1 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Anti-Cancer Compound Library
  • Ferroptosis Compound Library
  • Targeted Diversity Library

生物活性

iFSP1 is a potent, selective and glutathione-independent inhibitor of ferroptosis suppressor protein 1 (FSP1) (AIFM2) with an EC50 of 103 nM. iFSP1 selectively induces ferroptosis in GPX4-knockout cells which overexpressed FSP1. iFSP1 is able to sensitize a variety of human cancer cell lines to the ferroptosis inducer, such as (1S,3R)-RSL3 (HY-100218A)[1].

IC50 & Target

EC50: 103 nM (FSP1)[1]
体外研究
(In Vitro)

iFSP1 (0.001-1 μM; 24 hours) inhibits the Gpx4-knockout cell growth as a dose-dependent manner, but does not inhibit the wild type cell growth. Treatment with the ferroptosis inhibitor Lip-1 protects GPX4- knockout cells from iFSP1-induced ferroptosis[1].
iFSP1 (0.001-1 μM; 24 hours) is less efficient than genetic deletion of FSP1, whereas iFSP1 treatment in the FSP1-knockout background had no additive effect to RSL3-induced ferroptosis[1].
iFSP1 (3 μM; 24 hours) treatment results in an obvious toxicity of RSL3 in a panel of genetically engineered (FSP1-knockout) human cancer cell lines[1].
AIFM2: the flavoprotein apoptosis-inducing factor mitochondria-associated 2 is a previously unrecognized anti-ferroptotic gene. AIFM2, which is renamed ferroptosis suppressor protein 1 (FSP1)[1]

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line: Wild-type and Gpx4-knockout Pfa1 or HT 1080 cells overexpressing FSP1–HA
Concentration: 0.001-1 μM
Incubation Time: 24 hours
Result: Was toxic to cells that depend solely (no GPX4 expression detectable) on FSP1 function.

Cell Viability Assay[1]

Cell Line: NCl-H1437, NCl-H1437 FSP1 KO, U-373, U-373 FSP1 KO, MDA-MB-436, MDA-MB-436 FSP1 KO, SW620, SW620 FSP1 KO, MDA-MB-435S, MDA-MB-435S FSP1 KO, A549 and A549 FSP1 KO
Concentration: 3 μM
Incubation Time: 24 hours
Result: Sensitized a variety of human cancer cell lines to the ferroptosis inducer (1S,3R)-RSL3.

分子量

323.35

Formula

C20H13N5
CAS 号

150651-39-1
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 20 mg/mL (61.85 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.0926 mL 15.4631 mL 30.9262 mL
5 mM 0.6185 mL 3.0926 mL 6.1852 mL
10 mM 0.3093 mL 1.5463 mL 3.0926 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: 2 mg/mL (6.19 mM); Suspended solution; Need ultrasonic

    此方案可获得 2 mg/mL (6.19 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Doll S, et al. FSP1 is a glutathione-independent ferroptosis suppressor.Nature. 2019 Nov;575(7784):693-698.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务